CClinicalTrials.gg
Not yet recruitingNCT07702500NeurobiomUpdated Sep 8, 2026

Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia

An interventional study of EEG in Neonate, Asphyxia and EEG, sponsored by Centre Hospitalier Universitaire, Amiens. Not yet recruiting at 1 site in France. Open to participants aged 1 Day and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
1 Day and older
Sex
All
01

Study summary

Current diagnostic methods rely primarily on clinical symptoms, supplemented by brain imaging and physiological tests. However, these signs of injury only become apparent once significant damage has occurred, thus delaying intervention and compromising the effectiveness of treatments. Therefore, there is a need to develop new markers to develop preventive measures for the consequences of perinatal asphyxia.

The primary objective is to compare cognitive and motor development at 18 months in three populations (PA, at risk of PA, and Control) defined on the basis of clinical, biological, and neural criteria.

02

Conditions studied

  • Neonate
  • Asphyxia
  • EEG
  • Eye Tracking
  • Biomarkers

Browse trials for

Keywords

  • Neonate
  • asphyxia
  • anoxo ischemia
  • EEG
  • Eye tracking
  • Biomarkers
03

Who can participate

Ages eligible
1 Day and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Non-Perinatal Asphyxia Cohort:

The non-PA cohort includes:

  • Full-term infants (born between 36 and 42 weeks of gestation), clinically "normal" and without PA. Infants must have birth weights within the normal range for their gestational age.
  • Satisfactory Apgar scores at 1, 3, and 5 minutes, indicating good health.
  • Meet specific biochemical biomarker criteria as defined by the study protocols.
  • No major complications should occur during pregnancy or delivery.

    • At-Risk Perinatal Asphyxia Cohort:

The at-risk PA cohort includes newborns who are:

  • Identified by healthcare professionals as being at risk based on criteria that do not exceed the diagnostic thresholds for PA but whose combined assessment of maternal, fetal, and neonatal medical criteria suggests risk factors and early signs of potential PA,
  • OR
  • Classified as such based on biochemical markers identified in WP1 (see WP1).

    • Confirmed Perinatal Asphyxia Cohort:

The PA cohort includes:

  • Newborns diagnosed with PA and treated with hypothermia. The inclusion criteria for this group allow for various modes of delivery, complications during pregnancy and delivery, and a range of gestational ages, as long as they meet the criteria for PA.
  • Birth weight must be ≥ 1800 g.
  • Apgar scores at 1, 3, and 5 minutes must indicate potential complications or difficulties.
  • Specific biochemical markers indicative of PA must be present

Exclusion criteria

Exclusion Criteria:

  • Full-term newborn not meeting inclusion criteria
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Non-Perinatal Asphyxia

    * Full-term infants (born between 36 and 42 weeks of gestation), clinically "normal" and without PA. Infants must have birth weights within the normal range for their gestational age. * Satisfactory Apgar scores at 1, 3, and 5 minutes, indicating good health. * Meet specific biochemical biomarker criteria as defined by the study protocols. * No major complications should occur during pregnancy or delivery.

    Device: EEG

  • Active comparator
    At-Risk Perinatal Asphyxia

    The at-risk PA cohort includes newborns who are: * Identified by healthcare professionals as being at risk based on criteria that do not exceed the diagnostic thresholds for PA but whose combined assessment of maternal, fetal, and neonatal medical criteria suggests risk factors and early signs of potential PA, * OR * Classified as such based on biochemical markers identified in WP1 (see WP1)

    Device: EEG

  • Active comparator
    Confirmed Perinatal Asphyxia

    * Newborns diagnosed with PA and treated with hypothermia. The inclusion criteria for this group allow for various modes of delivery, complications during pregnancy and delivery, and a range of gestational ages, as long as they meet the criteria for PA. * Birth weight must be ≥ 1800 g. * Apgar scores at 1, 3, and 5 minutes must indicate potential complications or difficulties. * Specific biochemical markers indicative of PA must be present

    Device: EEG

Interventions

  • DeviceEEG

    electroencephalogram

05

What researchers measure

Primary outcomes

  1. variation of Cognitive development in the three populations

    variation of Cognitive development in the three populations (PA, at risk of PA, and Control) Cognitive development is determined with EEG, eye tracking and questionnaire

    Time frame: at 18 months

  2. variation of motor development in the three populations

    variation of motor development in the three populations (PA, at risk of PA, and Control) motor development is determined by mouvement analysis

    Time frame: at 18 months

Secondary outcomes

  1. Identification of biochemical and protein markers of PA

    biochemical and protein markers are oxygen level, pH, lactates, glucose, IL-1β, IL-6, TNF-α

    Time frame: at 18 months

  2. Identification of EEG markers of PA

    EEG is Electroencephalography

    Time frame: at 18 months

  3. correlation between biochemical, protein, and EEG markers

    Time frame: at 18 months

  4. correlation between biochemical markers at birth and behavioral measurements at 18 months

    Analyze correlations between biochemical, protein, and EEG markers at birth and behavioral and neural measurements at 18 months.

    Time frame: at 18 months

06

Study locations

1 site
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07702500
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Fabrice Wallois, Pr
Contact
wallois.fabrice@chu-amiens.fr
33+3 22 087775

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion